Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

YMN-A02 for Advanced pMMR Colorectal Cancer With Liver Metastases

20 maggio 2026 aggiornato da: Xingchen Peng, West China Hospital

A Phase I Clinical Trial of YMN-A02 in Patients With Advanced pMMR Colorectal Cancer and Liver Metastases: Safety, Tolerability, and Preliminary Efficacy

This study was a prospective, single-center, open-label, single-arm, multi-dose ascending phase Ⅰ clinical trial. The investigators constructed a TM10-LNP mRNA preparation encoding CTLA-4 antibody and TGF-β trap bifunction protein (YMN-A02 bifunction RNA preparation). The aim of this study is to provide a new strategy for overcoming the immune tolerance of liver tumors and improving the response rate of immunotherapy. The investigators planned to enroll patients with advanced pMMR liver metastasis from colorectal cancer who failed standard treatment. A modified "3+3" design was used, and 10 patients were expected to be enrolled. There were four dose groups of 100μg, 250μg, 500μg and 1000μg. The trial used a modified "3+3" dose climbing design, in which one subject was set as a sentinel patient in the initial 100μg dose group. If the subject did not experience DLT during the DLT observation period, the dose was judged safe and escalation to the next group occurred. If DLT occurred, 3 additional subjects in this group would be required for further evaluation. In the subsequent 250μg, 500μg, and 1000μg dose groups, three subjects were enrolled first in each group: if there was no DLT, the number of subjects was increased. If ≥2 of the 3 cases had DLT, the escalation was terminated. If DLT occurred in 1 out of 3 subjects, 3 additional observations would be made in the same dose group. If the incidence of DLT in the total 6 subjects did not exceed 1/6 after the supplement, the escalation could be escalated. Otherwise, the escalation was terminated and the dose was considered as intolerable.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

10

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Peng Xingchen Peng
  • Numero di telefono: 86-17723609529
  • Email: pxx2014@163.com

Luoghi di studio

    • Sichuan
      • Chengdu, Sichuan, Cina, 610041
        • West China Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  1. Signed the informed consent form approved by the ethics committee.
  2. 18-70 years old; ECOG performance status 0-1.
  3. Histologically or cytologically confirmed colorectal cancer with liver metastases, molecularly classified as pMMR (presence of other distant metastases allowed).
  4. Patients who have failed or are intolerant to standard therapy, or who refuse standard therapy.

    1. For patients with RAS/BRAF wild-type and eligible for targeted therapy: enrollment allowed only after disease progression on a prior standard regimen containing anti-EGFR or anti-VEGF monoclonal antibody.
    2. For patients with BRAF V600E mutation: enrollment allowed only after failure of a prior BRAF inhibitor-containing chemotherapy regimen.
    3. For patients who do not meet the above molecular characteristics: enrollment allowed only after failure of at least two prior lines of systemic chemotherapy (including a platinum-containing regimen).
  5. At least one measurable liver metastasis (CT scan long diameter ≥10 mm, slice thickness ≤5 mm).
  6. Life Expectancy≥3 months.
  7. Adequate Major Organ Function (all within 14 days before randomization):

    1. Hemoglobin ≥80 g/L (no transfusion within 14 days); absolute neutrophil count >1.5×10⁹/L; platelet count ≥80×10⁹/L.
    2. Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN (or ≤5×ULN in the presence of liver metastases); creatinine clearance ≥60 mL/min (Cockcroft-Gault formula).
    3. Left ventricular ejection fraction (LVEF) ≥50%.
  8. Good compliance, and family agrees to cooperate with survival follow-up.

Exclusion Criteria:

  1. Participation in another interventional drug trial within 4 weeks before enrollment.
  2. Prior or concurrent other malignancy, except: carcinoma in situ of the cervix, cutaneous squamous cell carcinoma, superficial bladder tumor, or any other malignancy that has been curatively treated and recurrence-free for ≥5 years.
  3. Poorly controlled heart disease or clinical symptoms, including but not limited to: NYHA class ≥2 heart failure, unstable angina, myocardial infarction within 1 year, or clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.
  4. Pregnant or breastfeeding women.
  5. Active infection, including but not limited to: active tuberculosis, systemic bacterial or fungal infection (NCI-CTCAE v5.0 grade ≥2), HIV infection, active HBV (HBV DNA >ULN), or active HCV (HCV RNA >ULN).
  6. History of substance abuse that cannot be abstained from, or history of psychiatric disorders.
  7. Active or history of autoimmune disease (including but not limited to uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism, etc.). Exceptions: vitiligo controlled with only topical agents; childhood asthma completely resolved without any intervention in adulthood. Patients with asthma requiring bronchodilators for medical intervention are excluded.
  8. Prior vaccination with any mRNA-based drug or mRNA formulation.
  9. Prior participation in any clinical trial involving lipid nanoparticle (LNP) formulations.
  10. Contraindications to intravenous infusion.
  11. History of drug abuse, or any medical, psychological, or social condition (e.g., alcoholism or drug addiction) that, in the investigator's judgment, may affect study compliance.
  12. Known allergy, hypersensitivity, or intolerance to any component (active substance or excipients) of the study drug; history of severe allergy to drugs, food, or vaccines, including but not limited to anaphylactic shock, angioedema of the larynx, anaphylactic dyspnea, allergic purpura, thrombocytopenic purpura, or Arthus reaction.
  13. Plan to conceive (either female subject or partner of male subject) from screening through 12 months after the last dose.
  14. Any concurrent condition that, in the investigator's judgment, may compromise patient safety or interfere with study completion.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: YMN-A02 100 μg Group
Enrolled subjects will receive a 100 μg intravenous infusion.
Enrolled subjects will receive a 100 μg intravenous infusion according to their assigned dose group. The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment. The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose. The DLT observation period is from the first infusion to 14 days after the third infusion.
Altri nomi:
  • YMN-A02
Sperimentale: YMN-A02 250 μg Group
Enrolled subjects will receive a 250 μg intravenous infusion.
Enrolled subjects will receive a 250 μg intravenous infusion according to their assigned dose group. The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment. The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose. The DLT observation period is from the first infusion to 14 days after the third infusion.
Sperimentale: YMN-A02 500 μg Group
Enrolled subjects will receive a 500 μg intravenous infusion.
Enrolled subjects will receive a 500 μg intravenous infusion according to their assigned dose group. The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment. The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose. The DLT observation period is from the first infusion to 14 days after the third infusion.
Sperimentale: YMN-A02 1000 μg Group
Enrolled subjects will receive a 1000 μg intravenous infusion.
Enrolled subjects will receive a 1000 μg intravenous infusion according to their assigned dose group. The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment. The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose. The DLT observation period is from the first infusion to 14 days after the third infusion.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Occurrence of Dose-Limiting Toxicity (DLT)
Lasso di tempo: From first dose to 14 days after the third dose, approximately Day 0 to Day 42
Observe and record the occurrence of DLTs. DLT is defined as treatment-related adverse events or clinically significant laboratory abnormalities occurring during the DLT observation period, graded according to NCI CTCAE v5.0.
From first dose to 14 days after the third dose, approximately Day 0 to Day 42

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-Free Survival (PFS)
Lasso di tempo: Within 2 years after the first dose
Assess disease progression per RECIST v1.1, calculating the time from start of treatment to first documented disease progression or death from any cause.
Within 2 years after the first dose
Objective Response Rate (ORR)
Lasso di tempo: Within 6 months after the first dose
Tumor response assessed per RECIST v1.1 for solid tumors. ORR is the proportion of patients whose tumor volume reduction reaches a predefined value and is maintained for a minimum required duration, calculated as the sum of complete response (CR) and partial response (PR) rates.
Within 6 months after the first dose

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Changes in Peripheral Blood Lymphocyte Subsets
Lasso di tempo: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Peripheral blood lymphocytes will be isolated from whole blood using lymphocyte separation medium. Flow cytometry will be used to detect T cells, B cells, macrophages, NK cells, and regulatory T cells (Tregs).
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Percentage of Dendritic Cells Expressing Maturation/Activation Markers
Lasso di tempo: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Dendritic cells (DCs) will be isolated from peripheral blood and labeled with antibodies against surface markers CD80, CD86, and MHC class II molecules. Flow cytometry will be performed to determine the percentage of DCs positive for each marker. Maturation and activation status are assessed based on these percentages
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Tumor-Infiltrating CD8+ T Cells
Lasso di tempo: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Tumor tissue sections will be stained to identify CD8+ T cells, including stem-like and exhausted CD8+ T cell subsets. Confocal microscopy and flow cytometry (using single-cell suspensions from tumor tissue) will be used to observe the infiltration status of these cells.
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Cytokine Levels Associated with Delayed-Type Hypersensitivity (DTH)
Lasso di tempo: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Plasma will be collected 24-72 hours after administration. ELISA kits will be used to measure the levels of cytokines including IL-12, IFN-γ, IL-2, and IL-10 to assess the cellular immune response and the impact of the product on immune function.
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

30 luglio 2026

Completamento primario (Stimato)

30 giugno 2028

Completamento dello studio (Stimato)

30 giugno 2028

Date di iscrizione allo studio

Primo inviato

26 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

20 maggio 2026

Primo Inserito (Effettivo)

28 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2026(890)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi